BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 20308654)

  • 21. Younger age of cancer initiation is associated with shorter telomere length in Li-Fraumeni syndrome.
    Tabori U; Nanda S; Druker H; Lees J; Malkin D
    Cancer Res; 2007 Feb; 67(4):1415-8. PubMed ID: 17308077
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A French retrospective study on clinical outcome in 102 choroid plexus tumors in children.
    Siegfried A; Morin S; Munzer C; Delisle MB; Gambart M; Puget S; Maurage CA; Miquel C; Dufour C; Leblond P; André N; Branger DF; Kanold J; Kemeny JL; Icher C; Vital A; Coste EU; Bertozzi AI
    J Neurooncol; 2017 Oct; 135(1):151-160. PubMed ID: 28677107
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Choroid plexus tumors in adult and pediatric populations: the Cleveland Clinic and University Hospitals experience.
    Bahar M; Hashem H; Tekautz T; Worley S; Tang A; de Blank P; Wolff J
    J Neurooncol; 2017 May; 132(3):427-432. PubMed ID: 28290001
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A novel TP53 germline mutation in a family with a history of multiple malignancies: case report and review of the literature.
    Agarwalla PK; Dunn IF; Turner CD; Ligon KL; Schneider KA; Smith ER
    Pediatr Neurosurg; 2008; 44(6):501-8. PubMed ID: 19127094
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer.
    Berns EM; Foekens JA; Vossen R; Look MP; Devilee P; Henzen-Logmans SC; van Staveren IL; van Putten WL; Inganäs M; Meijer-van Gelder ME; Cornelisse C; Claassen CJ; Portengen H; Bakker B; Klijn JG
    Cancer Res; 2000 Apr; 60(8):2155-62. PubMed ID: 10786679
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Germ line BAX alterations are infrequent in Li-Fraumeni syndrome.
    Barlow JW; Mous M; Wiley JC; Varley JM; Lozano G; Strong LC; Malkin D
    Cancer Epidemiol Biomarkers Prev; 2004 Aug; 13(8):1403-6. PubMed ID: 15298965
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumor protein 53 mutations and inherited cancer: beyond Li-Fraumeni syndrome.
    Palmero EI; Achatz MI; Ashton-Prolla P; Olivier M; Hainaut P
    Curr Opin Oncol; 2010 Jan; 22(1):64-9. PubMed ID: 19952748
    [TBL] [Abstract][Full Text] [Related]  

  • 28. P53 mutation analysis of colorectal liver metastases: relation to actual survival, angiogenic status, and p53 overexpression.
    de Jong KP; Gouw AS; Peeters PM; Bulthuis M; Menkema L; Porte RJ; Slooff MJ; van Goor H; van den Berg A
    Clin Cancer Res; 2005 Jun; 11(11):4067-73. PubMed ID: 15930341
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cancer phenotype correlates with constitutional TP53 genotype in families with the Li-Fraumeni syndrome.
    Birch JM; Blair V; Kelsey AM; Evans DG; Harris M; Tricker KJ; Varley JM
    Oncogene; 1998 Sep; 17(9):1061-8. PubMed ID: 9764816
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Germline TP53 mutations and Li-Fraumeni syndrome.
    Varley JM
    Hum Mutat; 2003 Mar; 21(3):313-20. PubMed ID: 12619118
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic impact of TP53 mutations and P53 protein overexpression in supratentorial WHO grade II astrocytomas and oligoastrocytomas.
    Peraud A; Kreth FW; Wiestler OD; Kleihues P; Reulen HJ
    Clin Cancer Res; 2002 May; 8(5):1117-24. PubMed ID: 12006527
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chromosomal imbalances in choroid plexus tumors.
    Rickert CH; Wiestler OD; Paulus W
    Am J Pathol; 2002 Mar; 160(3):1105-13. PubMed ID: 11891207
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The TP53 gene promoter is not methylated in families suggestive of Li-Fraumeni syndrome with no germline TP53 mutations.
    Finkova A; Vazna A; Hrachovina O; Bendova S; Prochazkova K; Sedlacek Z
    Cancer Genet Cytogenet; 2009 Aug; 193(1):63-6. PubMed ID: 19602465
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The TP53 mutation, R337H, is associated with Li-Fraumeni and Li-Fraumeni-like syndromes in Brazilian families.
    Achatz MI; Olivier M; Le Calvez F; Martel-Planche G; Lopes A; Rossi BM; Ashton-Prolla P; Giugliani R; Palmero EI; Vargas FR; Da Rocha JC; Vettore AL; Hainaut P
    Cancer Lett; 2007 Jan; 245(1-2):96-102. PubMed ID: 16494995
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Case Report : Li-Fraumeni Syndrome with Central Nervous System Tumors in Two Siblings.
    Fang Z; Su Y; Sun H; Ge M; Qi Z; Hao C; Qian S; Ma X
    BMC Pediatr; 2021 Dec; 21(1):588. PubMed ID: 34961499
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic impact of TP53 mutation status for adult patients with supratentorial World Health Organization Grade II astrocytoma or oligoastrocytoma: a long-term analysis.
    Ständer M; Peraud A; Leroch B; Kreth FW
    Cancer; 2004 Sep; 101(5):1028-35. PubMed ID: 15329912
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Germline TP53 mutations and single nucleotide polymorphisms in children.
    Valva P; Becker P; Streitemberger P; Lombardi GM; Rey G; Guzman CA; Preciado MV
    Medicina (B Aires); 2009; 69(1 Pt 2):143-7. PubMed ID: 19414295
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mutations and deletions of the TP53 gene predict nonresponse to treatment and poor outcome in first relapse of childhood acute lymphoblastic leukemia.
    Hof J; Krentz S; van Schewick C; Körner G; Shalapour S; Rhein P; Karawajew L; Ludwig WD; Seeger K; Henze G; von Stackelberg A; Hagemeier C; Eckert C; Kirschner-Schwabe R
    J Clin Oncol; 2011 Aug; 29(23):3185-93. PubMed ID: 21747090
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ABCB1 and GST polymorphisms associated with TP53 status in breast cancer.
    Nordgard SH; Ritchie MD; Jensrud SD; Motsinger AA; Alnaes GI; Lemmon G; Berg M; Geisler S; Moore JH; Lønning PE; Børresen-Dale AL; Kristensen VN
    Pharmacogenet Genomics; 2007 Feb; 17(2):127-36. PubMed ID: 17301692
    [TBL] [Abstract][Full Text] [Related]  

  • 40. TP53 mutational pattern in Spanish and Polish non-small cell lung cancer patients: null mutations are associated with poor prognosis.
    de Anta JM; Jassem E; Rosell R; Martínez-Roca M; Jassem J; Martínez-López E; Monzó M; Sánchez-Hernández JJ; Moreno I; Sánchez-Céspedes M
    Oncogene; 1997 Dec; 15(24):2951-8. PubMed ID: 9416838
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.